.png){kind=icon}
.png){kind=icon}
Return
Real-world insights on switching aflibercept dosage for enhanced outcomes in age-related macular degeneration (RISE-AMD): Safety data
.png){kind=icon}
OA
AI
M
C
K
M
N
S
A
S
C
H
Y
M
L
DOI：10.1111/aos.70160.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To evaluate real-world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age-related macular degeneration (nAMD).
Keywords:
adverse events
aflibercept 8 mg
age-related macular degeneration
Eylea 8 mg
intraocular inflammation
intraocular pressure
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
2.8
Papers:
1.1W
Citations:
1.1W
Organization
Cited Papers